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Abstract
Background: KIOM-CRC#BP3B (BP3B) is a novel herbal prescription that is composed of three plant extracts. Our
preliminary study identified that BP3B exhibited potent anti-proliferative activity against various types of cancer cell
lines in vitro. Because the in vivo anti-tumor effect of BP3B is not evaluated before clinical trial, we want to test it
using patient’s samples.
Methods: To confirm the in vivo anti-cancer effect of BP3B, we used genetically characterized patient-derived colon
tumor xenograft (PDTX) mouse model. Anti-cancer activity was evaluated with apoptosis, proliferation, angiogenesis
and histological analysis.
Results: Oral administration of BP3B significantly inhibited the tumor growth in two PDTX models. Furthermore,
TUNEL assay showed that BP3B induced apoptosis of tumor tissues, which was associated with degradation of
PARP and Caspase 8 and activation of Caspase 3. We also observed that BP3B inhibited cancer cell proliferation by
down-regulation of Cyclin D1 and induction of p27 proteins. Inhibition of angiogenesis in BP3B-treated group was
observed with immunofluorescence staining using CD31 and Tie-2 antibodies.
Conclusion: These findings indicated that BP3B has a strong growth-inhibitory activity against colon cancer in
in vivo model and will be a good therapeutic candidate for treatment of refractory colon cancer.
Keywords: BP3B, Colon cancer, Patient-derived tumor xenograft, Medicinal plant
Background
Colorectal cancer is a serious health problem that has
progressively increased to be one of the most common
cancers worldwide [1]. Combined therapeutic approaches,
such as surgery, chemotherapy and radiation were applied
to patients with colorectal cancer. Enormous progress has
been made during last decade using fluorouracil (FU) to
treat colorectal cancer, with a doubling in dose intensity
or tumor response through combined treatment with leu-
covorin (LV) or bevacizumab or through continuous intra-
venous administration of FU instead of a bolus injection
[2]. In recent years, the chemotherapeutic agents (irinote-
can (CPT-11) and oxaliplatin) have resulted in significant
progress in the treatment of advanced colorectal cancer.
Initial treatment with irinotecan infused FU/LV, com-
monly known as IFL, resulted in significant increases in
response rate, time to disease progression and median
overall survival [3, 4]. However, retrospective analyses
suggested that the administration of IFL might be limited
to patients with a performance status of 0 [5]. When
oxaliplatin infused LVFU-2 regimen was compared with a
treatment of oxaliplatin plus LVFU-2, known as FOL-
FOX4, the latter treatment significantly increased the re-
sponse rate and the time to progression to 9.0 months.
The increase in median survival from 14.7 to 16.2 months
did not reach statistical significance [6]. Unfortunately, the
metastasis and recurrence of colorectal cancer after cura-
tive surgery or resistance to chemotherapy eventually lead
to a half of colon cancer patients still die [7].
Since cancer is a very complex disease with multiple
known and unknown regulatory mechanisms, treating of
cancer based on single target mechanism could be less
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effective than using multi-target strategy [8, 9]. Combin-
ation chemotherapies, commonly known as cocktail ther-
apies, targeting diverse abnormalities of cancer, have
shown better treatment outcome from various clinical
studies [10, 11]. In terms of this fact, natural herbal medi-
cines traditionally used for various disease management,
could be valuable sources in developing anti-cancer drugs
due to their multi-target/multi-component nature. Herbal
prescription may amplify the therapeutic efficacies of each
herbal component, exhibiting maximum outcome with
less side effects [12]. The traditional usage of these medi-
cinal plants has been successfully performed for prevent-
ing asthma, reducing edema, relieving fever, cough,
hemorrhages, diarrhea and protecting liver [12].
For research of tumor biology or evaluation of antican-
cer drugs, in vivo xenograft models have been performed
extensively [13, 14]. However, most of these in vivo
models are based on a limited number of cancer cells pre-
viously isolated from tumors and selected prior to im-
plantation in animals. Unfortunately, these in vivo models
were difficult to reproduce the tumor microenvironment
and cancer cell adaptation to the innate immune system,
both of which are essential to architecture of the primary
tumors, proliferation and metastasis [15]. In contrast,
patient-derived tumor xenograft (PDTX) model obtained
by engraftment of patient biopsies transplanted directly
into non-obese diabetic/severe combined immunodefi-
ciency (NOD/SCID) mice, subcutaneously, seems to be
able to reduce the biologic differences between the
primary patient tumor and the in vivo model [16]. In
recent years, PDTX models that have been characterized
for predicting drug response in various cancer types [17]
and used in numerous preclinical studies [18].
The present study aimed to evaluate the anti-cancer
effect of KIOM-CRC#BP3B (BP3B), which is novel herbal
prescription of ethanol extract of three medicinal plants on
colon cancer using PDTX model. The components of
BP3B are Descurainia sophia seed, Peucedanum radix
(Peucedanum praeruptorum Dunn.) and Alnus japonica
branch. Several reports including our previous study
identified that the seeds of D. sophia contained several
cytotoxic and anti-inflammatory substances to induce the
death of various cancer cell lines in vitro [19–21]. We also
showed that pyranocoumarins from P. praeruptorum
possessed considerably significant multidrug-resistant re-
versal activity in multidrug resistant MES-SA/Dx5 cancer
cells [22]. A. japonica as well contained anti-proliferative
and pro-apoptotic compounds that kill some cancer cells
such as human leukemia and prostate cancer [23, 24].
Although these three plant materials possessed potential
anti-cancer activities, it is very important to measure the
anti-cancer activity of herbal mixtures in a reliable in vivo
model system. To confirm the anti-tumorigenic activity of
BP3B against colon cancer, we investigated the changes of
histopathological characteristics, proliferation, angiogenesis
and apoptotic cell death in colon tumor tissues.
Methods
Reagents
Antibodies against Pecam-1 (M-20:sc-1506),PARP (H-
250:sc-7150) and Tie-2 (H-176:sc-9026) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
bodies against p27kip1 (#3688) and Cleaved-Caspase-3
(#9661) were obtained from Cell Signaling (Beverly, MA).
Anti-Ki67 antibody was purchased from Vector laborator-
ies (Burlingame, CA). Anti-β-actin (A5441) was purchased
from Sigma-Aldrich (St. Louis, MO). The 4’6-Diamino-2-
phenylindole dihydrochloride was purchased from Thermo
Fisher (Waltham, MA).
Preparation of KIOM-CRC#BP3B
The dried seeds of Descurainia sophia, roots of Peucedanum
praeruptorum Dunn. and branches of Alnus japonica were
purchased from Kwangmyungdang Medicinal Herbs Co.
(Ulsan, Republic of Korea). The identities of each herb
material were formally confirmed by Dr. Go Ya Choi, K-
Herb Research Center, Korea Institute of Oriental Medicine.
All voucher specimens have been deposited at KM-
Convergence Research Division, Korea Institute of Oriental
Medicine. A whole extract of each herb was separately pre-
pared. In brief, dried plant materials were finely pulverized
and immersed in 70% (v/v) ethanol (100 g/L). Then, the
solvent extraction was performed by maceration at room
temperature (48 h, three times). The extract solutions were
filtered through a Whatman filter paper No. 2 (Whatman
International, Maidstonem, UK), concentrated using a
EYELA rotary evaporation system (Tokyo Rikakikai, Tokyo,
Japan) and dried a WiseVen vacuum oven (WOW-70, Dai-
han Scientific, Seoul, Republic of Korea) to produce a 70%
ethanol extract. The dried powder of extract was homoge-
nized and then stored in the dark at 4 °C until use. KIOM-
CRC#BP3B was prepared by mixing the three herbal extracts
at an equal ratio, 1:1:1 (w/w/w). KIOM-CRC#BP3B was
dissolved in 0.5% Na-carboxymethyl cellulose (Na-CMC)
solution right before being used in animal experiments.
Generation of colon PDTX model and in vivo drug
efficacy test
The 6-8 week old male nu/nu mice (Orient Bio, Seongnam,
Korea) were used for in vivo studies and all experiments
using immunodeficient mice were carried out in accord-
ance with the guidelines approved by Institutional Animal
Care and Use Committees of Gachon University. Fresh
surgical tumor tissues (F0) were collected immediately after
surgery from Gil hospital (Incheon, Korea) and cut into 1
~ 2 mm3-sized pieces in antibiotics-containing RPMI
medium. Written informed consent was obtained from
each patient and the study was approved by the Gil hospital
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ethics committee. Tumor fragments were implanted into
subcutaneous pockets of mice, which were made in each
side of the lower back. When the tumor size reached to
100 ~ 200 mm3, those samples were called F1, subsequently
divided into pieces for passaging in vivo to make F2 xeno-
graft tumors. When F2 tumor size reached to 100 ~
200 mm3, collected and cut into 1 ~ 2 mm3 sized pieces
and implanted into subcutaneous layer on the backs of
mice to make F3. When F3 tumor size reached to 100 ~
200 mm3, mice were randomly divided into 4 groups with
5 mice per each group. Mutation status of important
cancer-related genes and patient information of colon
PDTX samples is listed in Table 1.
One group was treated twice per week with intraperitoneal
injection of 5 mg/kg oxaliplatin in PBS and other groups
were treated once daily orally with low dose (250 mg/kg) or
high dose (500 mg/kg) of BP3B dissolved in 0.5% Na-CMC
(w/v). Tumor diameters were serially measured with a digital
caliper every 2-3 days and tumor volumes were calculated
using the following formula: V = (L ×W2)/2, V = volume, L
= length and W=width. On day 21, mice were sacrificed
and tumor tissues were collected, fixed with 10% formalin
and embedded in paraffin. Remaining tissues were kept on
-80 °C deepfreezer for isolating protein and RNA.
TUNEL assay
Terminal deoxynuclotidyl transferase-mediated deoxyuri-
dine triphosphate nick-end-labeling (TUNEL) assay was
performed to measure nuclear DNA fragmentation in
apoptotic cells using DeadEnd™ Fluorometric TUNEL Sys-
tem (Promega, Madison, WI), according to the manufac-
turer’s instruction. In brief, paraffin sections of colon
tumor samples were deparaffinized in xylene and rehy-
drated in a series of graded alcohols and fixed in 4% para-
formaldehyde for 30 min and permeabilized with 20 μg/ml
proteinase K for 10 min at room temperature. The tissue
section were then incubated with TUNEL reaction buffer
in a 37 °C humidified chamber for 1 h, rinsed twice with
2xSSC and PBS and then incubated with DAPI for 1 min
at room temperature. Stained apoptotic cells were visual-
ized by fluorescence microscopy.
Immunohistochemistry and immunofluorescence assay
Paraffin sections of colon tumor samples were deparaffi-
nized in xylene and rehydrated in a series of graded alco-
hols and antigen was retrieved in 0.01 M sodium citrate
buffer. Samples were incubated with 3% H2O2 for 10 min
and followed by 1 h blocking in 1% bovine serum albumin
in PBS. The slides were incubated overnight at 4 °C,
followed by incubating sections with secondary antibody
using ABC kit (Vector laboratories) for 1 h at room
temperature. Then, samples were developed with diami-
nobezidine (Vector Laboratories) reagent and counter-
stained with hematoxylin and mounted with permount.
To quantify the immunostaining intensity of TUNEL,
Ki67, CD31 or Tie-2-positive cells, we used and ImmunoRa-
tio software by analyzing the control and treatment groups.
The percentage of positively stained nuclear area was calcu-
lated by using a color deconvolution for separating the stain-
ing components (diaminobezidine and hematoxylin) in at
least 3 fields per each slide. The results were presented as
percentage of treated group compared to control one.
Western blot analysis
Collected colon tumor tissues were lysed in a buffer con-
taining 25 mM HEPES (pH 7.5), 150 mM NaCl, 1% Triton
X-100, 10% glycerol, 5 mM EDTA and a protease inhibitor
cocktail. Protein concentration was determined using the
bicinchoninic acid assay. For western blotting, equal
amount of proteins were separated by SDS-polyacrylamide
gel electrophoresis, followed by transfer to Immobilon®-P
PVDF transfer membrane (Millipore, Bedford, MA). After
immunoblotting using specific antibodies, proteins were
visualized by chemiluminescence, according to the manu-
facturer’s instructions (Pierce, Rockford, IL).
Statistical analysis
These results were represented as the mean ± SD values.
The differences between groups were determined using
2-tailed student’s tests and the differences were consid-
ered significant when the P-values were ≤0.05.
Results
BP3B significantly inhibits tumorigenic growth in PDTX
model
To investigate the ability of BP3B on the inhibition of
tumor growth in vivo, nu/nu mice were implanted with
different types (102 F and 115 F) of patient colon tumors
and assigned to the following four groups (n = 5 mice per
patient per treatment group) for treatment with 0.5% Na-
CMC only (control), oxaliplatin (5 mg/kg), 250 mg/kg or
Table 1 Characteristics of PDTX patient samples
115 F 102 F
Age 83 50
Sex F F
pT (primary status) 3 4a
pM (distant metastasis) 0 1
pN (Lymph node status) 0 2b






Microsatellite instability Stable Stable
KRAS mutation status G13D WT
EGFR overexpression - -
p53 expression + +
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500 mg/kg of BP3B. As shown in Fig. 1a and b, BP3B ad-
ministration significantly retarded tumor growth by ~70%
compared with control mice. Body weights of the mice
were not significantly altered by BP3B administration
compared with those of the control group (Fig. 1c) and
any defects of other tissues or organs were found in mice.
These results suggest that BP3B significantly suppressed
tumorigenic growth and did not cause any severe toxicity.
Histology analysis of xenograft tumors
To obtain more complete insight into the inhibitory effect
of BP3B on tumor growth, histological studies on tumor tis-
sue sections with H&E staining were performed. As shown
in Fig. 2, tumor cells in the control group had well-defined
cell borders and hyperchromatic nuclei (a and e). However,
tumors treated with oxaliplatin (5 mg/kg) (b and f), 250 mg/
kg (c and g) or 500 mg/kg (d and h) of BP3B showed signifi-
cant differences from the corresponding control groups. For
instance, tumor cells were accompanied by chromatin
condensation, formation of apoptotic bodies. Especially, high
dose BP3B-treated tumor tissues revealed more clear
apoptotic characteristics and cell death phenotype.
BP3B treatment promotes apoptotic cell death in
xenograft tumors
Based on previous study, we hypothesized that BP3B may
have anti-tumor activity through induction of cancer cell
apoptosis. Therefore, we assessed whether antitumor activ-
ities of BP3B in colon cancer xenografts are exerted through
activation of apoptosis. An apoptosis detection kit (TUNEL)
was used to identify apoptotic cell death induced by BP3B.
As shown in Fig. 3a, oxaliplatin (5 mg/kg), low dose
(250 mg/kg) and high dose (500 mg/kg) of BP3B -treated
tumor tissues showed significant apoptosis index compared
with control group. We also confirmed BP3B mediated cell
apoptosis using western blot analysis (Fig. 3b). As a marker
for apoptosis, degradation of PARP and activation of
Caspase 3 proteins were detected in PDTX samples. As
expected, PARP was degraded in drug-treated samples. In
opposite way, activated Caspase 3 was increased in two
types of PDTX tissues by treatment of BP3B. Although there
were no high differences between oxaliplatin and high dose
of BP3B-treated 102 F tumors in TUNEL assay, western blot
analysis shown the reliable differences of apoptosis between
two groups. These data indicate that BP3B induced apop-
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Fig. 1 The inhibitory effect of BP3B on in vivo tumor growth in PDTX model. Patient-derived colon tumors were subcutaneously established in
BALB/c nude mice. Representative PDTX samples were resected on day 21 (five tumors per group) showing the difference in tumor volumes
between vehicle (0.5% Na-CMC), extracts (250 and 500 mg/kg) and oxaliplatin (5 mg/kg) (a). When the tumors reached 100-200 mm3 in size, mice
were treated with drugs for 3 weeks. Tumor sizes were measured every 3 days using a caliper and tumor volumes were calculated (b) and body
weight (c). ** p < 0.01 and *** p < 0.001













Fig. 2 Histological analysis of tumor samples after BP3B administration. After sacrificing the mice, colon tumor tissues from vehicle (a and e),
oxaliplatin (5 mg/kg, b and f), low dose (250 mg/kg, c and g) and high dose (500 mg/kg, d and h)-treated group were fixed and checked with
hematoxylin/eosin-staining. Cell nuclei were stained with hematoxylin (purple). Red arrows indicate the representative cells with apoptotic
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Fig. 3 Induction of tumor apoptosis by BP3B in PDTX model. a To measure the apoptotic tissues in BP3B-treated tumors, TUNEL assay was performed.
Apoptotic cells were visualized into green and nuclei were stained with DAPI (blue). The intensity of image was calculated with ImmunoRatio software.
Scale bars are 50 μm. ** p < 0.01 and *** p < 0.001. b Expression pattern of apoptosis-related proteins (PARP and Cleaved-caspase3) was confirmed with
western blot after lysis of tumor tissues. Densitometric analysis was performed with Image J software
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BP3B regulates cell cycle related proteins in PDTX models
To investigate the effect of BP3B on the proliferation of
colon cancer cells, we first conducted an immunohisto-
chemistry using intrinsic proliferation marker, Ki67. As
shown in Fig. 4a, Ki67 positive cells were highly detected
in control groups compared with oxaliplatin and BP3B-
treated tumor tissues. This result suggests that BP3B sig-
nificantly suppresses cell proliferation of in vivo PDTX
tumor. To further understand how BP3B inhibits colon
cancer cell proliferation, the effect of BP3B on the cell
cycle regulators, p27 and cyclin D1, was checked using
western blot analysis. As shown in Fig. 4b, cyclin D1
expression was reduced, but p27 expression was in-
creased upon treatment with BP3B. Especially, high dose
of BP3B (500 mg/kg) induced significant reduction of
cyclin D1 and increase of p27. These results suggest that
BP3B inhibits cancer cell proliferation and induces apop-
tosis by regulating cell cycle related proteins.
BP3B suppresses angiogenesis in xenograft tumors
Angiogenesis has been known well as an important role in
tumor growth, progression and metastasis [25–27] There-
fore, we further examined whether BP3B inhibits angiogen-
esis in xenograft model. Immunofluorescence staining with
antibodies against CD31 and Tie-2 revealed that vehicle-
treated group formed intact blood vessel in tumor samples.
However, oxaliplatin and BP3B-treated groups showed
markedly decreased angiogenesis in tumor tissues (Fig. 5
and Additional file 1: Figure S1). These data suggest that
BP3B also inhibits the formation of neo-angiogenesis in
PDTX tissues.
Discussion
KIOM-CRC#BP3B is a novel herbal prescription that is
composed of three plant materials in equal weighs. Descur-
ainia sophia (L.) Weeb ex Prantl (Flixweed) is a member of
the family Brassicaceae that is widely distributed in north-
eastern China and its seed has been broadly used in folk
medicine as a cure for throat diseases and viral diseases
such as measles and smallpox. Several studies of this plant
material have reported that it contains diverse secondary
metabolites including cardiac glycoside, flavonoids, lac-
tones, lipids, nor-lignans, and coumarins with various bio-
logical activities such as cytotoxicity and anti-inflammatory
activity [28, 29]. The dried roots of Peucedanum praerup-
torum Dunn (Family Umbelliferae) are a well-known trad-
itional Chinese medicine. Several phytochemical and
pharmacological studies have shown that various couma-
rins are the major constituents of this plant and these have
diverse biological properties such as anti-inflammatory,
chemopreventive and neuroprotective effects [30–32].
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Fig. 4 Inhibition of cell proliferation by BP3B in PDTX model. a To check the effect of BP3B on cell proliferation, immunohistochemical analysis of
Ki67 was performed with drug-treated samples. Ki67 were stained into brown and nuclei were counterstained with hematoxylin (purple). The
intensity of Ki67-positive cell was calculated with ImmunoRatio software. Scale bars are 50 μm. * p < 0.05, ** p < 0.01, *** p < 0.001. b Expression
of cell proliferation markers (Cyclin D1 and p27) was confirmed with western blot. Densitometric analysis was performed with Image J software
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the bark of this plant has long been used in traditional
medicine in the treatment of fever, hemorrhage, diarrhea,
and alcoholism. Several scientific studies revealed that the
extract of A. japonica contains various biological com-
pounds with anti-adipogenic, anti-proliferative, and anti-
parasitic activities [33, 34]. In this study, we showed that
BP3B have similar or better therapeutic efficacy compared
with oxaliplatin (Fig. 1). Because herbal drugs have been
known to exhibit fewer side effects (12), combination ther-
apy with already clinically used drugs, such as oxaliplatin or
irrinotecan can increase the anti-cancer activity and show
synergistic effect of chemotherapy. Although we did not
identify the exact mechanism for anti-tumorigenic activity
of BP3B, it will be very valuable information for further
study and clinical trial.
Preclinical trial for validation of potential therapeutic
targets via in vivo model is regarded as an indispensable
procedure for anti-cancer drug development and make the
conquest of cancer or other diseases [35]. Recently, many
studies have adopted the PDTX technique to perform the
preclinical testing of anti-cancer drugs [36]. Previous
studies also indicated that transplantation of fresh surgical
specimens better represents the cellular and clinical pheno-
types of human cancers compared with traditional cell line-
based preclinical testing [37, 38]. Histological examination
also showed that PDTX model exhibited very similar hist-
ology and immunohistochemical phenotypes of patient’s
original tumors and maintained the invasive/metastatic
features even during serial subtransplantations in vivo. Ac-
cording to their gene expression patterns in breast cancer
samples, less than 5% of genes showed variation in expres-
sion between PDTX and the homologous primary tumor
[37, 39]. Although we did not present in this paper, we also














































Fig. 5 Suppression of angiogenesis by BP3B in PDTX model. To measure the status of tumor angiogenesis in BP3B-treated tumors, immunofluor-
escence analysis of CD31 was performed. CD31 positive cells were visualized into red and nuclei were stained with DAPI (blue). The intensity of
image was quantified with ImmunoRatio software. Scale bars are 50 μm. * p < 0.05
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histologic architecture and pathologic characteristics to that
of the original tumors [38]. Established PDTX models of
colon cancer were good systems for evaluating the efficacy
of anti-tumor drug (Fig. 1). In addition, these models will
provide very important tools for developing the novel drugs
against drug-resistant tumors, such as cetuximab, using Ras
wild-type and mutant samples.
Conclusion
This study indicated that ethanol extract of dried seeds of
Descurainia sophia, roots of Peucedanum praeruptorum
Dunn. and branches of Alnus japonica has a strong
growth-inhibitory activity against colon cancer in patient-
derived tumor xenograft model. BP3B will be a good thera-
peutic candidate for treatment of refractory colon cancer.
Additional file
Additional file 1: Figure S1. To measure the status of tumor
angiogenesis in BP3B-treated tumors, immunostaining of Tie-2 receptor
tyrosine kinase was performed with specific antibody (brown). The intensity
of Tie-2-positive cell was quantified with ImmunoRatio software. Cell nuclei
were stained with hematoxylin (blue). Scale bars are 50 mm. * p < 0.05.
(PDF 421 kb)
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